Biomarkers for Neurodegenerative Disorders: From Bench to Bedside

Dear Colleagues,

Our knowledge on neurodegenerative disorders is rapidly expanding. Molecular, neuropsychological and imaging markers are valuable tools for understanding the various mechanisms underlying these disorders. In addition, such biomarkers may be of clinical value, and some of them have been incorporated in diagnostic criteria and guidelines for neurodegenerative disorders, including Alzheimer’s disease. This Special Issue provides insights into the use of biomarkers in neurodegenerative disorders, including (but not limited to) Alzheimer’s disease, frontotemporal dementias, Lewy body dementia, Parkinson’s disease, atypical parkinsonian disorders and amyotrophic lateral sclerosis. Among others, fluid biomarkers (cerebrospinal fluid or blood), structural imaging biomarkers (atrophy), positron emission tomography (PET) biomarkers (amyloid- and/or tau-PET and others), neuropsychological testing and genetic biomarkers are especially important. Original research, review and case report papers are all acceptable. Papers on biomarkers related to basic mechanisms are welcome, but the main interest is on clinically meaningful biomarkers, their help in the (differential) diagnosis of patients with cognitive and movement disorders, and in selecting patients for newer or emerging treatments.

Dr. George P. Paraskevas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• dementia
• Alzheimer’s disease
• frontotemporal dementia
• dementia with Lewy bodies
• parkinsonism
• tau protein
• TDP-43
• α-synuclein
• Tau-PET
• amyloid-PET